Advertisement

Organisation › Details
Kynos Therapeutics Ltd.
Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. It is a spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism. Its innovative pipeline of first-in-class KMO inhibitors across key indications in inflammation, immunity and metabolism, was originally co-developed through a collaboration between GSK and the University of Edinburgh and is now exclusively licensed to Kynos. Based in Edinburgh, UK, the company is financed by equity investment led by Epidarex Capital joined by IP Group plc and Scottish Enterprise, as well as a grant from Innovate UK. *
![]() |
Start | 2020-03-05 established (s-off) |
Group | Falk Pharma (Group) | |
Predecessor | University of Edinburgh | |
![]() |
Industry | KMO inhibitor (kynurenine 3-monooxygenase inhibitor) |
Industry 2 | drug development | |
![]() |
Person | Mole, Damian (Kynos Therapeutics 2022204 CEO + Co-Founder) |
Person 2 | Roper, Elizabeth (Liz) (Epidarex Capital 2013– Partner before Chroma Therapeutics + Wellcome Trust VC team) | |
![]() |
Region | Sheffield, South Yorkshire |
Country | United Kingdom (GB) | |
Street | 1-3 Charter Square | |
City | S1 4HS Sheffield | |
Address record changed: 2024-11-01 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Kynos Therapeutics Ltd.. (4/7/22). "Press Release: Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor". Edinburgh. | ||
Record changed: 2024-11-01 |
Advertisement

More documents for Falk Pharma (Group)
- [1] Kynos Therapeutics Ltd.. (10/29/24). "Press Release: Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio". Freiburg....
- [2] Kynos Therapeutics Ltd.. (4/7/22). "Press Release: Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor". Edinburgh....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top